Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...
Pharmaceutical Technology on MSN4d
EC approves BMS’ Opdivo and Yervoy combo for HCCThe European Commission (EC) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in combination with the ...
Zacks Investment Research on MSN4d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCCBristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...
Opdivo vs. Keytruda This month there was disappointment for Bristol-Myers Squibb which has run into yet another hurdle trying to extend the use of its immuno-oncology blockbuster Opdivo into new ...
The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant ...
Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical ...
The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...
Squibb announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult ...
The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo ...
Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on Friday ...
Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback